PHASE I CLINICAL TRIALS FOR PSORIASIS TX

Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.

Related Videos
Related Content

Previewing Fall Clinical PA & NP Conference With James Del Rosso, DO

May 31st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Janssen Announces Positive Results From Guselkumab Psoriatic Arthritis Trial

May 31st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Pointers With Portela: Products to Build a Skin Care Routine

May 31st 2023

Michael Cameron, MD, FAAD, Shares Challenges, Insights Into Opening a New Practice

May 31st 2023

Previewing Fall Clinical PA & NP Conference With James Del Rosso, DO

May 31st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Janssen Announces Positive Results From Guselkumab Psoriatic Arthritis Trial

May 31st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Pointers With Portela: Products to Build a Skin Care Routine

May 31st 2023

Michael Cameron, MD, FAAD, Shares Challenges, Insights Into Opening a New Practice

May 31st 2023

Previewing Fall Clinical PA & NP Conference With James Del Rosso, DO

May 31st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Janssen Announces Positive Results From Guselkumab Psoriatic Arthritis Trial

May 31st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Pointers With Portela: Products to Build a Skin Care Routine

May 31st 2023

Michael Cameron, MD, FAAD, Shares Challenges, Insights Into Opening a New Practice

May 31st 2023
© 2023 MJH Life Sciences

All rights reserved.